Beta Bionics Reports 63% Revenue Growth to $27.3 Million Despite Increased Net Loss

Beta Bionics, Inc. reported significant financial growth in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved net sales of $27.3 million for the quarter, a 63% increase from $16.7 million in the same period last year. For the nine months ended September 30, 2025, net sales reached $68.1 million, up 52% from $44.7 million in the prior year. The increase in revenue was primarily driven by a rise in the number of single-use products sold, correlating with the expansion of the company's installed customer base and growth in new patient starts, which totaled 5,334 for the quarter, compared to 3,180 in the previous year.

Despite the revenue growth, Beta Bionics reported a net loss of $14.2 million for the third quarter, a 46% increase from a loss of $9.7 million in the same quarter of 2024. The nine-month net loss also widened to $59.7 million from $36.6 million year-over-year. The increase in losses was attributed to higher operating expenses, which rose to $32.2 million for the quarter, up 62% from $19.9 million in the prior year. This increase was driven by substantial investments in research and development, sales and marketing, and general administrative expenses, reflecting the company's focus on expanding its market presence and enhancing its product offerings.

Operationally, Beta Bionics has made strides in customer engagement, with 70% of new patient starts in the third quarter coming from individuals previously using multiple daily injections (MDI). The company has also expanded its reimbursement channels, with 23% of net sales generated through the Pharmacy Benefit Plan (PBP) channel, up from 13% in the prior year. This shift is expected to enhance long-term revenue potential as PBP sales typically lead to higher cumulative gross margins over time.

Looking ahead, Beta Bionics plans to continue investing in its product development pipeline, including the development of a bihormonal system that combines insulin and glucagon delivery, as well as a patch pump. The company has sufficient cash reserves, totaling approximately $274 million as of September 30, 2025, to support its ongoing operations and growth initiatives. However, management acknowledges the need for additional funding in the future to sustain its growth trajectory and meet operational demands. The company remains focused on expanding its market share and enhancing its product offerings to improve patient outcomes in diabetes management.